Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 101kWORD 26k
1 December 2014
Answer given by Ms Bieńkowska on behalf of the Commission
Question reference: E-006674/2014

In line with Article 168 TFEU Member States retain the responsibility ‘for the definition of their health policy and for the organisation and delivery of health services’. In addition to Directive 89/105 on the transparency of national decisions on pricing and reimbursement of medicines, the Commission encourages cooperation and dialogue amongst the stakeholders.

The Process of Corporate Responsibility in the Field of Pharmaceuticals addressed the issue of high prices of medicines. Some Member States are currently cooperating on the new improved hepatitis C treatments, seeking equitable access to them for patients.

In its communication ‘On effective, accessible and resilient health systems’ of April 2014, with reference to medicinal products, the Commission highlighted the need for ‘improved cooperation, increased transparency and better coordination to minimise any unintended effects that current national pricing systems may have in terms of accessibility throughout the EU’.

Legal notice